Market Overview

Ocular Therapeutix™ To Report Second Quarter 2018 Financial Results

Share:

Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company
focused on the formulation, development, and commercialization of
innovative therapies for diseases and conditions of the eye, today
announced that it will report second quarter ended June 30, 2018
financial results on Tuesday, August 7, 2018. Following distribution of
the earnings release via wire services, the Ocular Therapeutix
management team will host a live conference call and webcast at 4:30
p.m. Eastern Time to review the Company's financial results and provide
a general business update.

The live webcast can be accessed by visiting the Investors section of
the Company's website at investors.ocutx.com.
Please connect at least 15 minutes prior to the live webcast to ensure
adequate time for any software download that may be needed to access the
webcast. Alternatively, please call (844) 464-3934 (U.S.) or (765)
507-2620 (International) to listen to the live conference call. The
conference ID number for the live call will be 7875199. An archive of
the webcast will be available until November 7, 2018 on the Company's
website.

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the
formulation, development, and commercialization of innovative therapies
for diseases and conditions of the eye using its proprietary
bioresorbable hydrogel-based formulation technology. Ocular Therapeutix
has resubmitted an NDA for post-surgical pain for its lead product
candidate, DEXTENZA® (dexamethasone insert), which has completed Phase 3
clinical development for the treatment of ocular pain and inflammation
following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase 3
clinical development for the reduction of intraocular pressure in
patients with primary open-angle glaucoma and ocular hypertension. The
Company's earlier stage assets include OTX-TIC, an extended-delivery
travoprost intracameral implant for the reduction of intraocular
pressure in patients with glaucoma and ocular hypertension, as well as
sustained release intravitreal implants for the treatment of retinal
diseases. These intravitreal implants include OTX-TKI, a tyrosine kinase
inhibitor (TKI), and, in collaboration with Regeneron, OTX-IVT, an
extended-delivery protein-based anti-vascular endothelial growth factor
(VEGF) trap, both for the treatment of retinal diseases. Ocular
Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal
corneal incisions following cataract surgery.

View Comments and Join the Discussion!